Patents by Inventor Chris GABEL

Chris GABEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid molecules encoding nuclease-albumin fusion proteins
    Patent number: 12163165
    Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: December 10, 2024
    Assignee: Resolve Therapeutics, LLC
    Inventors: James Arthur Posada, Chris Gabel
  • Optimized binuclease fusions and methods
    Patent number: 12077790
    Abstract: The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: September 3, 2024
    Assignee: Resolve Therapeutics, LLC
    Inventors: James Arthur Posada, Sanjay Patel, Weihong Yu, Chris Gabel
  • OPTIMIZED BINUCLEASE FUSIONS AND METHODS
    Publication number: 20220112474
    Abstract: The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Application
    Filed: December 23, 2021
    Publication date: April 14, 2022
    Inventors: James Arthur POSADA, Sanjay PATEL, Weihong YU, Chris GABEL
  • THERAPEUTIC NUCLEASE-ALBUMIN FUSIONS AND METHODS
    Publication number: 20210355462
    Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Application
    Filed: March 30, 2021
    Publication date: November 18, 2021
    Inventors: James Arthur POSADA, Chris GABEL
  • Therapeutic nuclease-albumin fusions and methods
    Patent number: 10988745
    Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: April 27, 2021
    Assignee: RESOLVE THERAPEUTICS, LLC
    Inventors: James Arthur Posada, Chris Gabel
  • OPTIMIZED BINUCLEASE FUSIONS AND METHODS
    Publication number: 20190241878
    Abstract: The invention provides for optimized binuclease fusion proteins with increased pharmacokinetic properties. The optimized binuclease fusion proteins of the invention two or more nuclease domains (e.g., RNase and DNase domain) operably coupled to an Fc domain. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Application
    Filed: June 30, 2017
    Publication date: August 8, 2019
    Inventors: James Arthur POSADA, Sanjay PATEL, Weihong YU, Chris GABEL
  • THERAPEUTIC NUCLEASE-ALBUMIN FUSIONS AND METHODS
    Publication number: 20160251638
    Abstract: The invention provides for hybrid nuclease-albumin molecules with increased pharmacokinetic properties. The hybrid nuclease-albumin molecules of the invention have one or more nuclease domains (e.g., an RNase and/or DNase domain) operably coupled to an albumin, or a variant or fragment thereof. The invention also provides methods of treating or preventing a condition associated with an abnormal immune response.
    Type: Application
    Filed: October 31, 2014
    Publication date: September 1, 2016
    Inventors: James Arthur POSADA, Chris GABEL